Cambridge, United States
Biogen, founded in 1978, is a pioneering force in the biotechnology sector, with a particular focus on developing innovative therapies for serious neurological and neurodegenerative diseases. As indicated by their slogan, "Innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases," Biogen seeks to transform patients' lives while delivering value for shareholders.
Headquartered in the United States, with around 7,000 employees globally, Biogen operates through an extensive international network, including research operations in Cambridge, Massachusetts, and international headquarters in Baar, Switzerland. The company’s approach combines a deep understanding of human biology with cutting-edge technology to advance first-in-class treatments.
Despite a period since their last investment—$2.07M grant in April 2018—Biogen stands out as an established leader in the Health Care industry, offering a robust platform for investors seeking long-term growth in the dynamic Health and Wellness landscape.
